PHARMACOGENETICS

作品数：61被引量：168H指数：8
导出分析报告
相关领域：医药卫生更多>>
相关作者：曾苏更多>>
相关机构：浙江大学华中科技大学武汉市中心医院更多>>
相关期刊：《Engineering》《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》《Asian Journal of Andrology》《Frontiers of Medicine》更多>>
相关基金：国家重点基础研究发展计划国家自然科学基金瑞士科学基金国家高技术研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Personalized medicine and opioid use disorder
《World Journal of Psychiatry》2024年第9期1285-1288,共4页Dilek Kaya-Akyüzlü 
Opioid use disorder(OUD)is a major public health problem affecting millions of people worldwide.Although OUD is a chronic and relapsing disorder,a variety of pharmacological and non-pharmacological interventions are a...
关键词：Opioid use disorder Genetic vulnerability Treatment failures Personalized medicine PHARMACOGENETICS 
Impact of genetic variants in the solute carrier(SLC)genes encoding drug uptake transporters on the response to anticancer chemotherapy
《Cancer Drug Resistance》2024年第1期553-576,共24页Jose J.G.Marin Maria A.Serrano Elisa Herraez Elisa Lozano Sara Ortiz-Rivero Laura Perez-Silva Maria Reviejo Oscar Briz 
funding from CIBEREHD,Fondo de Investigaciones Sanitarias,Instituto de Salud Carlos Ⅲ co-funded by European Regional Development Fund/European Social Fund,“Investing in your future”)(PI19/00819,PI20/00189,PI23/00681,and PI22/00526);Junta de Castilla y León(SA074P20,GRS 2322/A/21,and SA113P23);FundacióMarato TV3(Ref.201916-31),Fundación AECC(AECC2023/2027);University of Salamanca(PC_TCUE21-23_011);Spain.Reviejo M was supported by a postdoctoral contract funded by the“Junta de Castilla y Leon”(SA113P23).
Cancer drug resistance constitutes a severe limitation for the satisfactory outcome of these patients.This is a complex problem due to the co-existence in cancer cells of multiple and synergistic mechanisms of chemore...
关键词：Cancer CHEMOTHERAPY PHARMACOGENETICS single nucleotide alteration single nucleotide polymorphism transportome 
Pharmacogenetics and pharmacogenomics in glaucoma therapeutics:the way to personalized therapy
《Chinese Medical Journal》2023年第21期2573-2575,共3页Shiyu Liao Lixiang Wang Xin Wei 
supported by grants from the Natural Science Foundation of China(No.82070954);the Innovative Spark Grant of Sichuan University(No.2018SCUH0062);1·3·5 project for disciplines of excellence–Clinical Research Incubation Project,West China Hospital,Sichuan University(No.2021HXFH057);the“0-1’”Innovation Research Project of Sichuan University(No.2022SCUH0036).
Glaucoma is a leading cause of irreversible optic nerve damage,with a significant proportion of patients(approximately 10%)suffering from blindness or severe visual field damage during their lifetime.^([1])The number ...
关键词：GLAUCOMA protective DAMAGE 
CYP2C9^(*)3 Increases the Ibuprofen Response of Hemodynamically Significant Patent Ductus Arteriosus in the Infants with Gestational Age of More Than 30 Weeks被引量：1
《Phenomics》2022年第1期72-77,共6页Xiang Chen Yuxi Chen Tiantian Xiao Xinran Dong Yulan Lu Yanyan Qian Huijun Wang Wenhao Zhou 
supported by Shanghai Municipal Science and Technology Major Project(Grant No.2017SHZDZX01).
Hemodynamically significant patent ductus arteriosus(hsPDA)is a severe condition in newborns.Ibuprofen is an effective treatment to reduce the severe complications and the need for surgical treatment.Several single-nu...
关键词：CYP2C9 IBUPROFEN Patent ductus arteriosus PHARMACOGENETICS 
Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer被引量：1
《Acta Pharmaceutica Sinica B》2021年第11期3406-3416,共11页Wenxiao Jiang Guiqing Cai Peter Hu Yue Wang 
Non-small cell lung cancer is recognized as the deadliest cancer across the globe.In some areas,it is more common in women than even breast and cervical cancer.Its rise,vaulted by smoking habits and increasing air pol...
关键词：Non-small cell lung cancer Personalized medicine PHARMACOGENOMICS PHARMACOGENETICS Drug resistance Vinca alkaloids Toxoids DNA replication inhibitors 
Drug-induced Fatty Liver Disease:Pathogenesis and Treatment被引量：1
《Journal of Clinical and Translational Hepatology》2021年第5期731-737,共7页Tea Omanovic Kolaric Vjera Nincevic Lucija Kuna Kristina Duspara Kristina Bojanic Sonja Vukadin Nikola Raguz-Lucic George Y Wu Martina Smolic 
The study was funded by a grant from Croatian Ministry of Science and Education(dedicated to multi-year institutional funding of scientific activity at the J.J.Strossmayer University of Osijek,Osijek,Croatia,under grant number:IP10-MEFOS-2019 to MS);Support from the Herman Lopata Chair in Hepatitis Research is also gratefully acknowledged(to GYW).
Metabolic dysfunction-associated fatty liver disease(commonly known as MAFLD)impacts global health in epidemic proportions,and the resulting morbidity,mortality and economic burden is enormous.While much attention has...
关键词：Metabolic dysfunction-associated fatty liver disease Drug-induced liver injury Reactive oxygen species Free fatty acids PHARMACOGENETICS 
“Pharmacogenetics of Cancer”-Cancer Drug Resistance special issue
《Cancer Drug Resistance》2020年第2期225-231,共7页Enrico Mini Stefania Nobili 
Pharmacogenetics and pharmacogenomics have expanded rapidly over the past years and represent one of the bases of precision medicine.The application of pharmacogenetic and pharmacogenomic approaches and tools for the ...
关键词：DOSAGE BASES initiating 
Pharmacogenetics of immunosuppressant drugs:A new aspect for individualized therapy
《World Journal of Transplantation》2020年第5期90-103,共14页Maurizio Salvadori Aris Tsalouchos 
In recent years,pharmacogenetics has emerged as an important tool for choosing the right immunosuppressant drug and its appropriate dose.Indeed,pharmacogenetics may exert its action on immunosuppressant drugs at three...
关键词：Immunosuppressant pharmacokinetics Immunosuppressant pharmacodynamics Immunosuppressant pharmacogenetics Immunosuppressant pharmacogenomics Transplantation Immunosuppressant drugs 
iGMDR:Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research
《Genomics, Proteomics & Bioinformatics》2020年第2期150-160,共11页Xiang Chen Yi Guo Xin Chen 
financially supported by the National Natural Science Foundation of China(Grant Nos.81830073 and 31571356)
Current pharmacogenetic studies have obtained many genetic models that can predict the therapeutic efficacy of anticancer drugs.Although some of these models are of crucial importance and have been used in clinical pr...
关键词：Genetic model PHARMACOGENETICS Anticancer drug CANCER Drug response 
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma被引量：2
《Cancer Drug Resistance》2019年第3期680-709,共30页Marta Alonso-Peña Anabel Sanchez-Martin Paula Sanchon-Sanchez Meraris Soto-Muñiz Ricardo Espinosa-Escudero Jose J.G.Marin 
This study was supported by the Biomedical Research Networking Center in Hepatic and Digestive Diseases-CIBERehd(EHD15PI05/2016);the Health Research Fund,Institute of Health Carlos III,Spain(PI16/00598,co-funded by the European Regional Development Fund/European Social Fund,"Investing in your future");the Spanish Ministry of Economy,Industry and Competitiveness(SAF2016-75197-R);the Regional Government of Castile and Leon(SA063P17);and the AECC Scientific Foundation(2017/2020);Spain.MAP,ASM and PSS were supported by a pre-doctoral contract by“Ministry of Education,Culture and Sports”,Spain(BOE-A-2015-9456 and BOE-B-2017-72875);REE was supported by a pre-doctoral contract funded by the“Junta de Castilla y León,Fondo Social Europeo”(EDU/574/2018).
Primary liver cancers constitute the fourth most deadly group of cancers.Their poor prognosis is due in part to the pre-existence and/or development,often during treatment,of powerful mechanisms accounting for the poo...
关键词：Anticancer drug CHEMORESISTANCE CHEMOTHERAPY CHOLANGIOCARCINOMA germline mutation HEPATOMA liver cancer somatic mutation 
全选清除导出
共7页<1234567>
检索报告 对象比较 聚类工具 使用帮助 返回顶部